Thomas Pleli
YOU?
Author Swipe
View article: Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Fig. S1. Apoptosis is not responsible for down-regulation of Dicer in HepG2 under hypoxic conditions. Western blot analysis of protein extracts from HepG2 cells cultured for 24 h under hypoxia (1% O2) (H) or normoxia (N) usin…
View article: Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Information
View article: Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Fig. S2. Tumor hypoxia increases EMT markers in HepG2 xenografts. Nude mice bearing HepG2 xenografts were sacrificed and the tumors were removed from the animals. Frozen sections of the tumors were stained with anti-E-cadheri…
View article: Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Table S1. Clinicopathological parameters of the patients with HCC. HBV, hepatitis B virus; HCV, hepatitis C virus
View article: Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Purpose: A role of Dicer, which converts precursor miRNAs to mature miRNAs, in the tumor-promoting effect of hypoxia is currently emerging in some tumor entities. Its role in hepatocellular carcinoma (HCC) is unknown.Experimental Design: H…
View article: Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Fig. S2. Tumor hypoxia increases EMT markers in HepG2 xenografts. Nude mice bearing HepG2 xenografts were sacrificed and the tumors were removed from the animals. Frozen sections of the tumors were stained with anti-E-cadheri…
View article: Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Fig. S3. Doxycyline-induced overexpression of Dicer in HCC cells. HepG2 (A) and Huh-7 (B) cells stably transfected with the inducible Dicer construct were incubated with or without doxycycline (Dox) for 24 h. C: HepG2 cells w…
View article: Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Fig. S1. Apoptosis is not responsible for down-regulation of Dicer in HepG2 under hypoxic conditions. Western blot analysis of protein extracts from HepG2 cells cultured for 24 h under hypoxia (1% O2) (H) or normoxia (N) usin…
View article: Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Fig. S3. Doxycyline-induced overexpression of Dicer in HCC cells. HepG2 (A) and Huh-7 (B) cells stably transfected with the inducible Dicer construct were incubated with or without doxycycline (Dox) for 24 h. C: HepG2 cells w…
View article: Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Purpose: A role of Dicer, which converts precursor miRNAs to mature miRNAs, in the tumor-promoting effect of hypoxia is currently emerging in some tumor entities. Its role in hepatocellular carcinoma (HCC) is unknown.Experimental Design: H…
View article: Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Supplementary Information
View article: Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition Open
Table S1. Clinicopathological parameters of the patients with HCC. HBV, hepatitis B virus; HCV, hepatitis C virus
View article: Supplementary Figure S1 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S1 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S1: Imaging of HCC by Gd-EOB-DTPA-enhanced MRI in TGFα/c-myc mice with an HCC.
View article: Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S2: Body weight of HepG2 xenograft-bearing mice treated with iRGD, control (Ctl.) peptide, PBS and doxorubicin.
View article: Supplementary Figure S3 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S3 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S3: Body weight of HepG2 (A) and Huh-7 (B) xenograft-bearing mice treated with iRGD, control (Ctl.) peptide, PBS and sorafenib (Sora).
View article: Data from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Data from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
iRGD is a derivative of the integrin-binding peptide RGD, which selectively increases the penetrability of tumor tissue to various coadministered substances in several preclinical models. In this study, we investigated the ability of iRGD …
View article: Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S4: Effect of sorafenib with or without iRGD on MAPK phosphorylation levels in the HepG2 xenografts from the different treatment groups.
View article: Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S2: Body weight of HepG2 xenograft-bearing mice treated with iRGD, control (Ctl.) peptide, PBS and doxorubicin.
View article: Supplementary Figure S3 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S3 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S3: Body weight of HepG2 (A) and Huh-7 (B) xenograft-bearing mice treated with iRGD, control (Ctl.) peptide, PBS and sorafenib (Sora).
View article: Supplementary Figure S1 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S1 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S1: Imaging of HCC by Gd-EOB-DTPA-enhanced MRI in TGFα/c-myc mice with an HCC.
View article: Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
Supplementary Figure S4: Effect of sorafenib with or without iRGD on MAPK phosphorylation levels in the HepG2 xenografts from the different treatment groups.
View article: Data from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Data from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Open
iRGD is a derivative of the integrin-binding peptide RGD, which selectively increases the penetrability of tumor tissue to various coadministered substances in several preclinical models. In this study, we investigated the ability of iRGD …
View article: Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques
Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques Open
performed the cytotoxicity and cellular uptake studies by MTT and flow cytometry, respectively.S
View article: Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques
Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques Open
Today, efficient delivery of sorafenib to hepatocellular carcinoma remains a challenge for current drug formulation strategies. Incorporating the lipophilic molecule into biocompatible and biodegradable theranostic nanocarriers has great p…
View article: <b>Theranostic polymeric nanocarriers modified by enhanced gadolinium conjugation techniques</b>
<b>Theranostic polymeric nanocarriers modified by enhanced gadolinium conjugation techniques</b> Open
Background: Efficient delivery of the poorly water-soluble compound sorafenib still poses a challenge to current formulation strategies. To incorporate the lipophilic molecule into biocompatible and biodegradable theranostic nanoparticles …
View article: Selective targeting of tumor associated macrophages in different tumor models
Selective targeting of tumor associated macrophages in different tumor models Open
Tumor progression largely depends on the presence of alternatively polarized (M2) tumor-associated macrophages (TAMs), whereas the classical M1-polarized macrophages can promote anti-tumorigenic immune responses. Thus, selective inhibition…
View article: Supplementary Material for: Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors
Supplementary Material for: Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors Open
Background/Aims: Signaling of Gs protein-coupled receptors (GsPCRs) is accomplished by stimulation of adenylyl cyclase, causing an increase of the intracellular cAMP concentration, activation of the intracellular cAMP effectors protein kin…
View article: Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors
Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors Open
Background/Aims: Signaling of Gs protein-coupled receptors (GsPCRs) is accomplished by stimulation of adenylyl cyclase, causing an increase of the intracellular cAMP concentration, activation of the intracellular cAMP effectors protein kin…
View article: Type I Interferon Supports Inducible Nitric Oxide Synthase in Murine Hepatoma Cells and Hepatocytes and during Experimental Acetaminophen-Induced Liver Damage
Type I Interferon Supports Inducible Nitric Oxide Synthase in Murine Hepatoma Cells and Hepatocytes and during Experimental Acetaminophen-Induced Liver Damage Open
Cytokine regulation of high-output nitric oxide (NO) derived from inducible NO synthase (iNOS) is critically involved in inflammation biology and host defense. Herein, we set out to characterize the role of type I interferon (IFN) as poten…